Human protein tyrosine phosphatase inhibitors and methods of use
View Patent ↗The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.
1. A method for regulating vascularization of a tissue in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a HPTP-β inhibitor, wherein the HPTP-β inhibitor has the formula:
wherein:
R is a thiazolyl group that is substituted or unsubstituted;
R 1 is alkyl, phenyl, or benzyl, any of which is substituted or unsubstituted, or hydrogen;
R 2 is alkyl or alkoxy; and
R 3 is hydrogen or alkyl,
or a pharmaceutically-acceptable salt thereof.
2. The method of claim 1 , wherein the tissue in need of regulating vascularization is ocular tissue that needs repair from damage resulting from a diabetic pathology.
3. The method of claim 1 , wherein the HPTP-β inhibitor improves blood flow more than does an administration of a therapeutically-effective amount of VEGF.
4. The method of claim 1 , wherein the HPTP-β inhibitor binds to HPTP-β.
5. The method of claim 1 , wherein the subject is a human.
6. The method of claim 1 , wherein the administration is subcutaneous.
7. The method of claim 1 , wherein the HPTP-β inhibitor is:
8. The method of claim 1 , wherein the HPTP-β inhibitor is:
9. The method of claim 1 , wherein the HPTP-β inhibitor is: